A Visual Guide To US FDA's Evolutionary Decade In Review
An interactive timeline shows the news of the past decade and the evolution of US FDA policies. Click on each year for a full list of events and see the accompanying article.
You may also be interested in...ï»¿
A look back over FDA actions during the past 10 years shows the evolution of its policies on opioids, preemption, off-label promotion and use of real-world evidence.
Novartis co-leads industry forum on preapproval access that aims to share best practices and engage patient groups; Janssen is launching three pilots to leverage collection of preapproval access data.
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.